Name: FDA顧問團對強生公司的COVID-19疫苗進行審查 (FDA advisory panel reviews Johnson & Johnson’s COVID-19 vaccine)
Uploaded: 2021-02-26T18:25:29.000Z
Duration: 1 min 16 s

a crucial day for Johnson and Johnson's Covad 19 vaccine, as a panel of expert advisers meets Friday to review its safety and effectiveness.

強生公司的Covad 19疫苗的關鍵一天，作為一個專家顧問小組週五開會審查其安全性和有效性。

That panel of doctors, infectious disease experts and medical researchers is expected to vote in favor of the vaccines use at the end of the meeting.

那個由醫生、傳染病專家和醫學研究人員組成的小組預計將在會議結束時投票贊成使用疫苗。

進階被動語態

The Food and Drug Administration is then likely toe authorize it for emergency use within a day or so, with 3 to 4 million doses expected to be rolled out next week.

然後，食品和藥物管理局很可能在一天左右的時間內授權它用於應急使用，預計下週將推出300萬至400萬劑量。

That would make J and J's vaccine the third one available in the U.

這樣一來，J和J的疫苗將成為美國第三種可用的疫苗。

After those made by Pfizer beyond Tech and Madonna.

在那些由輝瑞公司製造的超越科技和麥當娜之後。

And it would be the only one that requires just a single injection.

而這將是唯一一個只需要一次注射的。

Unlike the other two, J and J's vaccine can be stored in normal refrigerator temperatures instead of ultra cold storage.

與其他兩種不同的是，J和J的疫苗可以在正常的冰箱溫度下儲存，而不是超低溫儲存。

這樣一來，配送啊，就容易多了。

 A trial found that J and J's vaccine was 66% effective at preventing moderate to severe cases of CO vid 19, and it was 100% effective at preventing hospitalizations 28 days after vaccination. 

一項試驗發現，J和J的疫苗對預防中度至重度COvid 19的有效率為66%，對預防接種後28天住院的有效率為100%。